Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,60%
1 099,68
-6,68
-0,60%
—1 106,361 105,681 109,291 096,52——
SIXC
Communications
SIXC
Communications
SIXC
+0,73%
614,77
+4,48
+0,73%
—610,29610,29616,60610,29——
SIXE
Energy
SIXE
Energy
SIXE
+0,64%
1 218,96
+7,74
+0,64%
—1 211,221 211,011 220,571 208,50——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,41%
1 757,95
+7,24
+0,41%
—1 750,711 753,101 762,131 743,30——
SIXM
Financials
SIXM
Financials
SIXM
+0,67%
632,39
+4,22
+0,67%
—628,17629,38634,09629,38——
SIXR
Staples
SIXR
Staples
SIXR
+0,48%
858,63
+4,06
+0,48%
—854,57855,71859,66855,45——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,14%
216,56
-0,31
-0,14%
—216,87216,87217,79216,17——
SIXT
Technology
SIXT
Technology
SIXT
+1,53%
3 616,28
+54,34
+1,53%
—3 561,943 571,443 628,583 562,15——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,12%
904,35
+1,04
+0,12%
—903,31903,26906,56901,18——
SIXV
Health care
SIXV
Health care
SIXV
+0,02%
1 481,79
+0,25
+0,02%
—1 481,541 482,481 488,461 474,18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,44%
2 410,47
+10,52
+0,44%
—2 399,952 404,452 418,812 398,09——
ALNOV:EPA
Novacyt SA
0,52 €
-18,75%
(-0,12) 1D
14-май, 17:35:10 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNOV...
Open
0,58 €
High
0,60 €
Low
0,50 €
Mkt. cap
37,79 млн
Avg. vol.
1,20 млн
Volume
5,35 млн
52-wk high
1,04 €
52-wk low
0,29 €
EPS
-0,38 €
Shares outstanding
72,59 млн
No. of employees
216
News stories
From sources across the web
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees216
Founded2006-ж., 3-июл.
Headquarters-
Sector-
Websitenovacyt.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
4,90 млн
4,90 млн
5,12 млн
5,12 млн
Cost of goods sold
1,64 млн
1,64 млн
2,06 млн
2,06 млн
Cost of revenue
1,64 млн
1,64 млн
2,06 млн
2,06 млн
Research and development expenses
1,02 млн
1,02 млн
1,03 млн
1,03 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,51 млн
5,51 млн
5,24 млн
5,24 млн
Operating expense
6,43 млн
6,43 млн
14,13 млн
14,13 млн
Total operating expenses
8,08 млн
8,08 млн
16,19 млн
16,19 млн
Operating income
-3,18 млн
-3,18 млн
-11,07 млн
-11,07 млн
Other non operating income
-31,00 миң
-31,00 миң
2,67 млн
2,67 млн
EBT including unusual items
-3,51 млн
-3,51 млн
-10,16 млн
-10,16 млн
EBT excluding unusual items
-3,12 млн
-3,12 млн
-10,55 млн
-10,55 млн
Income tax expense
-133,50 миң
-133,50 миң
-1,81 млн
-1,81 млн
Effective tax rate
3,80%
3,80%
17,85%
17,85%
Other operating expenses
-97,50 миң
-97,50 миң
7,86 млн
7,86 млн
Net income
-3,17 млн
-3,17 млн
-8,27 млн
-8,27 млн
Net profit margin
-64,76%
-64,76%
-161,60%
-161,60%
Earnings per share
-
-
-
-
Interest and investment income
177,00 миң
177,00 миң
-
-
Interest expense
-154,00 миң
-154,00 миң
-2,09 млн
-2,09 млн
Net interest expenses
23,00 миң
23,00 миң
-2,09 млн
-2,09 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,17 млн
-2,17 млн
-2,80 млн
-2,80 млн
Gain or loss from assets sale
-147,50 миң
-147,50 миң
-3,00 миң
-3,00 миң
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer